EMEA-001050-PIP01-10-M05 - paediatric investigation plan

ixekizumab

Key facts

• Invented name:
  Taltz
• Active Substance:
  ixekizumab
• Therapeutic area:
  Dermatology
• Decision number:
  P/0087/2020
• PIP number:
  EMEA-001050-PIP01-10-M05
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of psoriasis
• Route(s) of administration:
  Subcutaneous use
• Contact for public enquiries:

  Eli Lilly Nederland B.V.

  E-mail: [e-mail]; Tel. [phone]

• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  18/03/2020

Decision

P/0087/2020: EMA decision of 18 March 2020 on the acceptance of a modification of an agreed paediatric investigation plan for ixekizumab (Taltz) (EMEA-001050-PIP01-10-M05)

AdoptedReference Number: EMA/124408/2020